Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Sep 24, 2018 4:55pm EDT
Atara Biotherapeutics Appoints Cancer Research and Clinical Development Veteran, Roy Baynes, to its Board of Directors Sep 11, 2018 8:00am EDT
Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies Sep 06, 2018 7:30am EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 06, 2018 4:50pm EDT
Atara Biotherapeutics Announces Second Quarter 2018 Financial Results and Recent Operational Progress Aug 01, 2018 8:00am EDT
Atara Biotherapeutics to Participate in the Canaccord Genuity 38th Annual Growth Conference Jul 31, 2018 4:45pm EDT
Atara Biotherapeutics Opens State-of-the-Art Operations and Manufacturing Facility to Support Robust Off-the-Shelf T-Cell Immunotherapy Pipeline Jun 25, 2018 8:00am EDT
Atara Biotherapeutics’ Tab-cel™ Achieves Positive Long-Term Outcomes in Phase 2 Studies of Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas Jun 15, 2018 2:30am EDT
Atara Biotherapeutics Announces Publication of New Research Linking Epstein-Barr Virus (EBV) Infection and Multiple Sclerosis (MS) Jun 13, 2018 8:00am EDT
